Amgen Inc. (AMGN) News
Filter AMGN News Items
AMGN News Results
|Loading, please wait...|
AMGN News Highlights
- For AMGN, its 30 day story count is now at 86.
- Over the past 24 days, the trend for AMGN's stories per day has been choppy and unclear. It has oscillated between 1 and 27.
- The most mentioned tickers in articles about AMGN are MRK, PSO and BMY.
Latest AMGN News From Around the Web
Below are the latest news stories about Amgen Inc that investors may wish to consider to help them evaluate AMGN as an investment opportunity.
Photo by marchmeena29/iStock via Getty Images Market Recap High dividend yield stocks finally give way to the S&P 500 in April. VYM finished the month with a 2.55% total return compared to 5.29% for SPY, the S&P 500 ETF. However, since November 1, 2020, VYM is about 491 basis points...
In this episode of Rule Breaker Investing, we review 5 Stocks for the Coronavirus, 5 Stocks for the Age of Miracles, and 5 Stocks I Own That You Should, Too. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. David Gardner: Last April, the market was in as dark a place as any of us have seen for more than 10 years -- the 35% loss of the S&P 500 in 32 days.
Photo by Neznam/iStock via Getty Images Introduction Arrowhead Pharmaceuticals (ARWR) is an extremely innovative biotech company with an integrated development platform that I describe in my previous piece on the company. It is built on the application of RNAi technology to promising drug development targeting a number of serious diseases....
High-quality pharmaceutical stocks come with steady business, low valuations and solid dividend.
The healthcare sector outperformed in the past year due to the pandemic.
Bristol-Myers Squibb Co (NYSE: BMY ) joined other drugmakers in missing first-quarter earnings consensus due to a decline in medical visits and new diagnoses as COVID-19 cases surged at the start of the year. Today, Merck & Co Inc (NYSE: MRK ) reported Q1 earnings and sales that trailed Wall Street expectations, citing an early-in-the-year pandemic surge. Yesterday, Amgen Inc (NASDAQ: AMGN ) cited the pandemic effect in reporting a drop in its Q1 … Full story available on Benzinga.com
CDC Foundation Launches National Program to Educate Older Adults and Caregivers about Preventing Falls and Fall Injuries
ATLANTA , April 29, 2021 /PRNewswire/ -- Today the CDC Foundation announced an important new initiative to prevent falls and fall injuries in older adults. Each year more than one in four older adults (age 65 and older) experience a fall, resulting in 3 million emergency department visits, 950,000 hospitalizations and 32,000 deaths. Many of these falls are preventable. Together, Amgen and the CDC Foundation, with leveraged technical resources from the Centers for Disease Control and Prevention (CDC), will support the project's development of user-friendly fall prevention resources for older adults and their caregivers. The five-year project will create digital resources to help older adults assess their risk of falls and develop a plan to mitigate that risk by speaking with their health...
Amgen ([[AMGN]] -7.9%) has issued an update on its clinical program for LUMAKRAS, a once-daily oral small molecule KRASG12C inhibitor being developed as second-line therapy for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).Based on FDA’s proposed post-marketing requirement for the drug, the company has...
Amgen Inc. (AMGN) Q1 2021 Earnings Conference Call April 27, 2021 5:00 PM ET Company Participants Arvind Sood - Vice President of Investor Relations Robert Bradway - Chairman and Chief Executive Officer Peter Griffith - Chief Financial Officer Murdo Gordon - Executive Vice President, Global Commercial Operations David Reese -...
Amgen’s (AMGN) shares fell around 8% in early trading on Wednesday as the biopharmaceutical company reported disappointing results. Revenues fell 4% year-on-year to $5.9 billion, missing analysts’ estimate of $6.3 billion. The company reported a 12% year-on-year decline in non-GAAP EPS to $3.70, missing consensus estimates of $4.04 per share. Amgen’s Chairman and CEO, Robert A. Bradway said, "While our business continued to be impacted by the COVID-19 pandemic particularly in the first two months of the quarter, we are encouraged by strong volume trends in many of our newer products and remain confident in the outlook for the full year.